2013
DOI: 10.1248/bpb.b13-00544
|View full text |Cite
|
Sign up to set email alerts
|

Inhibitors of ATP Release Inhibit Vesicular Nucleotide Transporter

Abstract: Vesicular nucleotide transporter (VNUT) is responsible for vesicular ATP storage in ATP-secreting cells. In the present study, we examined the effects on VNUT-mediated transport of ATP release inhibitors such as ATP-binding cassette (ABC) proteins, hemichannels, maxi anion channels and P2X 7 receptor. The ATP transport activity of proteoliposomes containing purified human VNUT was blocked by glibenclamide, carbenoxolone, 18 α-glycyrrhetinic acid, flufenamic acid, arachidonic acid and A438079 without the format… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
11
0

Year Published

2016
2016
2019
2019

Publication Types

Select...
4
2

Relationship

1
5

Authors

Journals

citations
Cited by 17 publications
(11 citation statements)
references
References 22 publications
0
11
0
Order By: Relevance
“…Thus, it is highly probable that there are VNUT-specific inhibitors among the intermediates of glycolysis, the TCA cycle, and β-oxidation or their derivatives. Consistent with this speculation, arachidonic acid inhibits VNUT with an ID50 of 6.5 μM [134]. Proteoliposomes containing purified VNUT and other vesicular neurotransmitter transporters provide a suitable screening system for exploring vesicular ATP release blockers.…”
Section: Development Of a Vesicular Atp Release Blockermentioning
confidence: 58%
See 3 more Smart Citations
“…Thus, it is highly probable that there are VNUT-specific inhibitors among the intermediates of glycolysis, the TCA cycle, and β-oxidation or their derivatives. Consistent with this speculation, arachidonic acid inhibits VNUT with an ID50 of 6.5 μM [134]. Proteoliposomes containing purified VNUT and other vesicular neurotransmitter transporters provide a suitable screening system for exploring vesicular ATP release blockers.…”
Section: Development Of a Vesicular Atp Release Blockermentioning
confidence: 58%
“…The facts that enhanced purinergic chemical transmission causes a wide variety of pathophysiological phenomena [1,2] and that VNUT −/− mice appear to be healthy and exhibit therapeutic effects towards the metabolic syndrome anticipate the development of vesicular ATP release blockers for therapeutic purposes. However, the VNUT inhibitors known so far are toxic and not specific to VNUT [4,34,134]. For example, glibenclamide, an inhibitor of the ABC transporter, also inhibits VNUT, with an ID50 being 1.6 μM [134].…”
Section: Development Of a Vesicular Atp Release Blockermentioning
confidence: 99%
See 2 more Smart Citations
“…More recently it was proposed that VNUT-dependent ATP release from spinal cord dorsal root neurons might originate neuropathic pain in mice ( Masuda et al, 2016 ). Furthermore, clodronate was identified as a novel inhibitor of VNUT for the treatment of neuropathic and inflammatory pain, opening up new therapeutic possibilities for other pathologies ( Kato et al, 2013 , 2017 ).…”
Section: Discussionmentioning
confidence: 99%